{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"NotEst","upperLimit":"NotEst","value":"31.0"},{"groupId":"OG001","lowerLimit":"30","upperLimit":"NotEst","value":"52.2"}]}],"title":"12 weeks :Core (N=113, 115)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6"},{"groupId":"OG001","value":"44.2"}]}],"title":"24 weeks: Overall (N=35, 43)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"Patients who had difficulty in tolerating their pain were allowed to take rescue medication after the 6-hour post-dose pain assessments. Permitted rescue medications included acetaminophen 500 mg and/ or codeine 30 mg as needed. If they had insufficient pain relief, patients were allowed to take a maximum of 30 mg of oral prednisolone as needed per day for 2 days followed by up to 20 mg of prednisolone as needed per day for 3 subsequent days within 7 days after randomization or after re-dose/injection administration.","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) consisted of all patients as randomized in core study who had taken at least one dose of study drug. \"12 weeks:Core\" consisted of patients taking rescue medication during baseline flare of Core study and \"24 weeks:Overall\" consisted of patients who took rescue medication during last post-baseline flare during 24 weeks.","reportingStatus":"POSTED","timeFrame":"during 12 weeks core, 24 weeks overall","title":"Percentage of Participants Who Took Rescue Medication","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}